Catherine Skari
-
Feb- 2020 -24 FebruaryEvents
Rare Disease Day 2020: Abundance of events & vast participation are expected in this year’s RDD
Observed every year on the last day of February and in the 29th of February in 2020, Rare Disease…
Read More » -
22 February
-
19 FebruaryTIF News
Applications now open for TIF’s Renzo Galanello Fellowship Programme 2020
TIF‘s Renzo Galanello Fellowship Programme is back again in 2020! A small number of physicians, specialists in the field…
Read More » -
8 FebruaryDelegation Visits 2020
A UNITED Onlus Delegation From Italy Visits TIF – 7 February 2020
In recent years the Federation has engaged in order to strengthen the dissemination and penetration of its resources and educational…
Read More » -
8 FebruaryNews
‘FAiTh – Fight Against Thalassemia Association’ presents its activities for January 2020
The ‘FAiTh – Fight Against Thalassemia’ group, a longtime member of TIF operating in Pakistan, is dedicated to support,…
Read More » -
Jan- 2020 -27 JanuaryClinical News
FDA grants Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease & β-thalassaemia
An investigational gene therapy for Sickle Cell Disease (SCD) and β-thalassaemia, known as ARU-1801, has been given Orphan Drug Designation an…
Read More » -
21 JanuaryNews
Chiesi Group and Apotex Inc. finalize agreement for the acquisition of Ferriprox® (Deferiprone)
Chiesi Farmaceutici and Apotex (together with its American subsidiary, ApoPharma Usa), a company engaged in haematology and in the…
Read More » -
17 JanuaryTIF News
TIF’s latest Newletter is out now!
Catch up with our most recent newsletter and get informed about TIF’S activities and achievements in the past few months!…
Read More » -
13 JanuaryClinical News
Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany
Bluebird bio, Inc. announced earlier today the launch of ZYNTEGLO™ in Germany, the company’s one-time gene therapy for patients…
Read More » -
9 JanuaryNews
Deferasirox Accord: A new generic of Exjade recommended for approval by the EMA
The Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency‘ (EMA) committee responsible for human medicines, has…
Read More »

